POST Online Media Lite Edition


Precipio appoints Kathleen LaPorte to board

Staff Writer |
Omaha, Neb., USA - Precipio, a specialty cancer diagnostics company, announced the appointment of Kathleen LaPorte to its board of directors as an independent member.

Article continues below

Ms. LaPorte is an executive and VC with 30 years experience building innovative life sciences companies.

She served as general partner with Sprout Group from 1993-2004 and was one of the founders of New Leaf Venture Partners.

She is a co-founder of Health Tech Capital, a group of healthcare technology focused private and corporate investors.

Ms. LaPorte served as chief business officer and later as CEO of Nodality, an immuno-oncology diagnostics company.

She has served on numerous private and public company boards with roles on audit, compensation, and nominating committees.